Urinary trypsin inhibitor attenuates hepatic ischemia-reperfusion injury by reducing nuclear factor-kappa B activation. 2009

Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
Department of General Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

BACKGROUND Urinary trypsin inhibitor (UTI) inhibits the inflammatory response and protects against ischemia-reperfusion (I/R) injury. The inflammatory response is mediated by nuclear factor-kappa B (NF-kappaB) and its related target genes and products such as vascular endothelial cell adhesion molecule and CXC chemokines. We aimed to assess the roles of those mediators in a UTI-treated mouse model of hepatic I/R injury. METHODS Treatment group 1 (UTI given 5 minutes prior to liver ischemia), treatment group 2 (UTI given 5 minutes after the anhepatic phase) and a control group were investigated. Blood and liver samples were obtained and compared at 1, 3, 6 and 24 hours after reperfusion. RESULTS Attenuation of pathological hepatocellular damage was greater in the treatment groups than in the control group (P<0.05). Compared with the control group, the UTI treatment groups showed significantly lower serum alanine aminotransferase and aspartate aminotransferase levels, decreased myeloperoxidase activity, and reduced NF-kappaB activation. Also downregulated was the expression of tumor necrosis factor-alpha, cytokine-induced neutrophil chemoattractant, and macrophage inflammatory protein-2 at the mRNA level. P-selectin protein and intercellular adhesion molecule-1 protein expression were also downregulated. In addition, the treatment group 1 showed a better protective effect against I/R injury than the treatment group 2. CONCLUSIONS UTI reduces NF-kappaB activation and downregulates the expression of its related mediators, followed by the inhibition of neutrophil aggregation and infiltration in hepatic I/R injury. The protective role of UTI is more effective in prevention than in treatment.

UI MeSH Term Description Entries
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D000210 Acute-Phase Reaction An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma. Acute Phase Response,Acute-Phase State,Reaction, Acute-Phase,Response, Acute-Phase,Acute Phase Reaction,Acute Phase Responses,Acute Phase State,Acute-Phase Response,Phase Response, Acute,Reaction, Acute Phase,Response, Acute Phase,State, Acute-Phase
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001219 Aspartate Aminotransferases Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1. Aspartate Aminotransferase,Aspartate Transaminase,Glutamic-Oxaloacetic Transaminase,SGOT,Aspartate Apoaminotransferase,Glutamate-Aspartate Transaminase,L-Aspartate-2-Oxoglutarate Aminotransferase,Serum Glutamic-Oxaloacetic Transaminase,Aminotransferase, Aspartate,Aminotransferase, L-Aspartate-2-Oxoglutarate,Aminotransferases, Aspartate,Apoaminotransferase, Aspartate,Glutamate Aspartate Transaminase,Glutamic Oxaloacetic Transaminase,Glutamic-Oxaloacetic Transaminase, Serum,L Aspartate 2 Oxoglutarate Aminotransferase,Serum Glutamic Oxaloacetic Transaminase,Transaminase, Aspartate,Transaminase, Glutamate-Aspartate,Transaminase, Glutamic-Oxaloacetic,Transaminase, Serum Glutamic-Oxaloacetic

Related Publications

Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
November 2014, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
May 2004, Brain research,
Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
April 2014, The Journal of surgical research,
Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
January 2009, Canadian journal of physiology and pharmacology,
Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
March 2007, Chinese medical journal,
Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
October 2013, Molecular biology reports,
Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
January 2015, Neuropsychiatric disease and treatment,
Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
October 2005, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
December 2012, The Journal of surgical research,
Yi-Jun Wu, and Qi Ling, and Xin-Hui Zhou, and Yan Wang, and Hai-Yang Xie, and Ji-Ren Yu, and Shu-Sen Zheng
March 2022, Bioengineered,
Copied contents to your clipboard!